From the brink of Nasdaq delisting last year due to non-compliance with the minimum bid price rule, this clinical-stage biotechnology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback